"To grow a business this fast, you have to have new thing after new thing after new thing that enhances the patient experience to get deeper into the patient community," Dexcom CEO Kevin Sayer said on an earnings call last summer. " The FDA is holding a public advisory committee meeting next month to determine whether the categorisation of Dexcom 's new series Continuous Glucose Monitoring System ( CGM ) can change from a tracking device only to a continuous glucose monitor that can be used for regulatory decisions . The device sends glucose data directly to iOS smartphones via a built - in Bluetooth capability , eliminating the need for a separate receiver device .
The FDA is holding a public advisory committee meeting next month to determine whether the categorisation of Dexcom 's new series Continuous Glucose Monitoring System ( CGM ) can change from a tracking device only to a continuous glucose monitor that can be used for regulatory decisions . The device sends glucose data directly to iOS smartphones via a built - in Bluetooth capability , eliminating the need for a separate receiver device .